HRP20220991T1 - Derivati piridina i njihova terapeutska uporaba kao inhibitora trpc6 - Google Patents
Derivati piridina i njihova terapeutska uporaba kao inhibitora trpc6 Download PDFInfo
- Publication number
- HRP20220991T1 HRP20220991T1 HRP20220991TT HRP20220991T HRP20220991T1 HR P20220991 T1 HRP20220991 T1 HR P20220991T1 HR P20220991T T HRP20220991T T HR P20220991TT HR P20220991 T HRP20220991 T HR P20220991T HR P20220991 T1 HRP20220991 T1 HR P20220991T1
- Authority
- HR
- Croatia
- Prior art keywords
- methoxy
- piperidin
- phenoxy
- pyridazin
- methanone
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- FYEHZCHYPSYCHO-UHFFFAOYSA-N C1(N)=NN=C(C(=C1)C)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(F)C=C1 Chemical compound C1(N)=NN=C(C(=C1)C)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(F)C=C1 FYEHZCHYPSYCHO-UHFFFAOYSA-N 0.000 claims 2
- XAOSVOZSYZXLDC-UHFFFAOYSA-N CCOC1=CC(N)=NN=C1C1CCN(CC1)C(=O)C1=NC=C(OC2=CC=C(C=C2)C(F)(F)F)C(OC)=C1 Chemical compound CCOC1=CC(N)=NN=C1C1CCN(CC1)C(=O)C1=NC=C(OC2=CC=C(C=C2)C(F)(F)F)C(OC)=C1 XAOSVOZSYZXLDC-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- NBFDGEIKHLFJLY-UHFFFAOYSA-N NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)C(F)(F)F)OC Chemical compound NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)C(F)(F)F)OC NBFDGEIKHLFJLY-UHFFFAOYSA-N 0.000 claims 2
- DTAHYUKCFJTZCI-UHFFFAOYSA-N NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)F)OC Chemical compound NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)F)OC DTAHYUKCFJTZCI-UHFFFAOYSA-N 0.000 claims 2
- NGVFJNKJEASNHO-UHFFFAOYSA-N NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC)OC Chemical compound NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=C(C=C1)OC)OC NGVFJNKJEASNHO-UHFFFAOYSA-N 0.000 claims 2
- WUUUUIADANIROZ-UHFFFAOYSA-N NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1)OCC Chemical compound NC1=CC(=C(N=N1)C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1)OCC WUUUUIADANIROZ-UHFFFAOYSA-N 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 206010070538 Gestational hypertension Diseases 0.000 claims 1
- 206010018374 Glomerulonephritis minimal lesion Diseases 0.000 claims 1
- 201000005624 HELLP Syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims 1
- KDZRRQSRUXMZAE-UHFFFAOYSA-N N1=C(C=C(C(=N1)C1CCN(CC1)C(=O)C1=CC(=C(OC2=CC=C(C=C2)C(F)(F)F)C=N1)OC)C)N Chemical compound N1=C(C=C(C(=N1)C1CCN(CC1)C(=O)C1=CC(=C(OC2=CC=C(C=C2)C(F)(F)F)C=N1)OC)C)N KDZRRQSRUXMZAE-UHFFFAOYSA-N 0.000 claims 1
- SMULRYIMTOWDEM-UHFFFAOYSA-N N1=NC(=CC(=C1C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1)C)N Chemical compound N1=NC(=CC(=C1C1CCN(CC1)C(=O)C1=NC=C(C(=C1)OC)OC1=CC=CC=C1)C)N SMULRYIMTOWDEM-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 102000003623 TRPC6 Human genes 0.000 claims 1
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 claims 1
- -1 [4-(6-amino-4-methyl-pyridazin-3-yl)-piperidin-1-yl]-(4-methoxy-5-phenoxy-pyridin-2 -yl) Chemical group 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (12)
1. Spoj odabran iz skupine koju čine:
[4-(6-amino-4-metil-piridazin-3-il)-piperidin-1-il]-[5-(4-fluoro-fenoksi)-4-metoksi-piridin-2-il]-metanon,
[4-(6-amino-4-metil-piridazin-3-il)-piperidin-1-il]-(4-metoksi-5-fenoksi-piridin-2-il)-metanon,
[4-(6-amino-4-metoksi-piridazin-3-il)-piperidin-1-il]-[5-(4-fluoro-fenoksi)-4-metoksi-piridin-2-il]-metanon,
[4-(6-amino-4-metoksi-piridazin-3-il)-piperidin-1-il]-[4-metoksi-5-(4-trifluorometil-fenoksi)-piridin-2-il]-metanon,
[4-(6-amino-4-metoksi-piridazin-3-il)-piperidin-1-il]-[4-metoksi-5-(4-metoksi-fenoksi)-piridin-2-il]-metanon,
[4-(6-amino-4-etoksi-piridazin-3-il)-piperidin-1-il]-[4-metoksi-5-(fenoksi)-piridin-2-il]-metanon,
5-etoksi-6-(1-{4-metoksi-5-[4-(trifluormetil)fenoksi]piridin-2-karbonil}piperidin-4-il)piridazin-3-amin,
i
6-(l-{4-metoksi-5-[4-(trifluormetil)fenoksi]piridin-2-karbonil}piperidin-4-il)-5-metilpiridazin-3-amin.
2. Spoj prema zahtjevu 1, naznačen time što je spoj [4-(6-amino-4-metil-piridazin-3-il)-piperidin-1-il]-[5-(4-fluoro-fenoksi)-4-metoksi-piridin-2-il]-metanon.
3. Spoj prema zahtjevu 1, naznačen time što je spoj [4-(6-amino-4-metil-piridazin-3-il)-piperidin-1-il]-(4-metoksi-5-fenoksi-piridin-2-il) )-metanon.
4. Spoj prema zahtjevu 1, naznačen time što je spoj [4-(6-amino-4-metoksi-piridazin-3-il)-piperidin-1-il]-[5-(4-fluoro-fenoksi)-4-metoksi -piridin-2-il]-metanon.
5. Spoj prema zahtjevu 1, naznačen time što je spoj [4-(6-amino-4-metoksi-piridazin-3-il)-piperidin-1-il]-[4-metoksi-5-(4-trifluorometil-fenoksi)-piridin-2-il]-metanon.
6. Spoj prema zahtjevu 1, naznačen time što je spoj [[4-(6-amino-4-metoksi-piridazin-3-il)-piperidin-1-il]-[4-metoksi-5-(4-metoksi-fenoksi)-piridin-2-il]-metanon.
7. Spoj prema zahtjevu 1, naznačen time što je spoj [4-(6-amino-4-etoksi-piridazin-3-il)-piperidin-1-il]-[4-metoksi-5-(fenoksi)-piridin-2-il]-metanon.
8. Spoj prema zahtjevu 1, naznačen time što je spoj 5-etoksi-6-(l-{4-metoksi-5-[4-(trifluormetil)fenoksi]piridin-2-karbonil}piperidin-4-il)piridazin-3-amin.
9. Spoj prema zahtjevu 1, naznačen time što je spoj 6-(1-{4-metoksi-5-[4-(trifluormetil)fenoksi]piridin-2-karbonil}piperidin-4-il)-5-metilpiridazin-3-amin.
10. Farmaceutski prihvatljiva sol spoja prema bilo kojem od zahtjeva 1 do 9.
11. Farmaceutski pripravak koji sadrži bilo koji od spojeva prema zahtjevu 1 do 9, ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 10, i izborno farmaceutski prihvatljivu pomoćnu tvar.
12. Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol prema zahtjevu 10, za uporabu u liječenju bolesti ili poremećaja koji se može ublažiti inhibicijom TRPC6, pri čemu je bolest ili poremećaj odabran iz skupine koji se sastoji od srčane hipertrofije, ishemije, ishemijske reperfuzijske ozljede, hipertenzije, plućne arterijske hipertenzije, idiopatske plućne arterijske hipertenzije, restenoze, kronične opstruktivne plućne bolesti, cistične fibroze, Alzheimerove bolesti, Parkinsonove bolesti, Huntingtonove bolesti, amiotrofične lateralne skleroze (ALS), poremećaja mozga izazvanih traumom, astme, kronične opstruktivne plućne bolesti, reumatoidnog artritisa, osteoartritisa, upalne bolesti crijeva, multiple skleroze, mišićna distrofija, Duchenneove mišićne distrofije, preeklampsije i hipertenzije izazvane trudnoćom, nealkoholnog steatohepatitisa, bolesti minimalnih promjena, žarišne segmentalne glomeruloskleroze (FSGS ), nefrotskog sindroma, dijabetičke nefropatije ili dijabetičke bolesti bubrega (DKD), kronične bolesti bubrega, bubrežne insuficijencije, završnog stadija bubrežne bolesti, ishemije ili ishemijske reperfuzijske ozljede, raka, IPF (idiopatske plućne fibroze), ARDS (sindroma akutne respiratorne bolesti), emfizema i dijabetesa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577883P | 2017-10-27 | 2017-10-27 | |
| US201862628313P | 2018-02-09 | 2018-02-09 | |
| EP20197194.2A EP3786160B1 (en) | 2017-10-27 | 2018-10-25 | Pyridine derivatives and therapeutic uses thereof as trpc6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220991T1 true HRP20220991T1 (hr) | 2022-11-11 |
Family
ID=64270818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220991TT HRP20220991T1 (hr) | 2017-10-27 | 2018-10-25 | Derivati piridina i njihova terapeutska uporaba kao inhibitora trpc6 |
| HRP20230502TT HRP20230502T1 (hr) | 2017-10-27 | 2018-10-25 | Inhibitori trpc6 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230502TT HRP20230502T1 (hr) | 2017-10-27 | 2018-10-25 | Inhibitori trpc6 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10889568B2 (hr) |
| EP (2) | EP3700902B8 (hr) |
| JP (2) | JP7217273B6 (hr) |
| KR (2) | KR20200125758A (hr) |
| CN (1) | CN111527078B (hr) |
| AU (2) | AU2018355743B2 (hr) |
| BR (1) | BR112020007818A2 (hr) |
| CA (1) | CA3078769A1 (hr) |
| CL (2) | CL2020001097A1 (hr) |
| CY (1) | CY1126109T1 (hr) |
| DK (2) | DK3786160T3 (hr) |
| ES (2) | ES2946274T3 (hr) |
| FI (1) | FI3700902T3 (hr) |
| HR (2) | HRP20220991T1 (hr) |
| HU (2) | HUE062460T2 (hr) |
| IL (2) | IL274039B (hr) |
| LT (2) | LT3786160T (hr) |
| MX (1) | MX2020004283A (hr) |
| PE (1) | PE20210154A1 (hr) |
| PH (1) | PH12020550503A1 (hr) |
| PL (2) | PL3700902T3 (hr) |
| PT (2) | PT3786160T (hr) |
| RS (2) | RS63535B1 (hr) |
| SA (1) | SA520411843B1 (hr) |
| SG (2) | SG10202011632RA (hr) |
| SI (2) | SI3700902T1 (hr) |
| TW (2) | TWI780246B (hr) |
| UA (1) | UA128474C2 (hr) |
| WO (1) | WO2019081637A1 (hr) |
| ZA (1) | ZA202002372B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220991T1 (hr) * | 2017-10-27 | 2022-11-11 | Boehringer Ingelheim International Gmbh | Derivati piridina i njihova terapeutska uporaba kao inhibitora trpc6 |
| JP7291711B2 (ja) * | 2018-02-15 | 2023-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｒｐｃ６阻害剤 |
| EP3752503A1 (en) * | 2018-02-16 | 2020-12-23 | Boehringer Ingelheim International GmbH | Inhibitors of trpc6 |
| IL315313A (en) * | 2018-08-24 | 2024-10-01 | Xeniopro GmbH | Aromatic molecules for use in the treatment of pathological conditions |
| EP3959206A1 (en) * | 2019-04-12 | 2022-03-02 | Boehringer Ingelheim International GmbH | Inhibitors of trpc6 |
| WO2021079962A1 (ja) * | 2019-10-24 | 2021-04-29 | 国立大学法人大阪大学 | 難聴の予防および／または治療用医薬組成物 |
| WO2021160625A1 (en) | 2020-02-11 | 2021-08-19 | Klinikum Rechts Der Isar | Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices |
| AR121846A1 (es) * | 2020-04-16 | 2022-07-13 | Teijin Pharma Ltd | Derivado de arilo o heteroarilo |
| KR20230004650A (ko) * | 2020-04-16 | 2023-01-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 호흡기 병태를 치료하기 위한 trpc6의 억제제 |
| CN113105318B (zh) * | 2021-02-23 | 2022-05-20 | 中山大学 | 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用 |
| IL310983A (en) | 2021-10-15 | 2024-04-01 | Boehringer Ingelheim Int | TRPC6 inhibitory compounds for the treatment of sepsis |
| WO2023106421A1 (ja) * | 2021-12-06 | 2023-06-15 | 国立大学法人熊本大学 | Trpc6の発現を抑制する方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| EP0591426A4 (en) | 1991-06-27 | 1996-08-21 | Univ Virginia Commonwealth | Sigma receptor ligands and the use thereof |
| JP3100984B2 (ja) | 1992-12-02 | 2000-10-23 | ファイザー・インク． | 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類 |
| ATE384048T1 (de) | 1998-09-22 | 2008-02-15 | Astellas Pharma Inc | Cyanophenyl-derivate |
| DK1259485T3 (da) | 2000-02-29 | 2006-04-10 | Millennium Pharm Inc | Benzamider og beslægtede inhibitorer for faktor Xa |
| AU8066701A (en) | 2000-07-20 | 2002-02-05 | Neurogen Corp | Capsaicin receptor ligands |
| US7196080B2 (en) * | 2001-06-15 | 2007-03-27 | Astellas Pharma Inc. | Phenylpyridinecarbonylpiperazinederivative |
| JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
| NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
| DE10222291A1 (de) | 2002-05-18 | 2003-11-27 | Schlafhorst & Co W | Faserbandzuführeinrichtung |
| CN1150176C (zh) | 2002-05-22 | 2004-05-19 | 上海医药工业研究院 | 芳烷酮哌嗪衍生物及其应用 |
| JP2008515972A (ja) | 2004-10-13 | 2008-05-15 | ニューロジェン・コーポレーション | メラニン濃縮ホルモン受容体のリガンドとしてのアリール置換８−アザビシクロ［３．２．１］オクタン化合物 |
| DE102005044814A1 (de) * | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| TWI325423B (en) | 2005-10-28 | 2010-06-01 | Lilly Co Eli | Kinase inhibitors |
| MX2008008337A (es) | 2005-12-21 | 2008-09-03 | Schering Corp | Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3. |
| JP5019768B2 (ja) | 2006-03-23 | 2012-09-05 | 独立行政法人科学技術振興機構 | 新規低分子化合物およびその製造方法 |
| CN101657430B (zh) | 2007-03-15 | 2013-05-01 | 诺瓦提斯公司 | 有机化合物及其用途 |
| JP5082538B2 (ja) | 2007-03-28 | 2012-11-28 | Ｄｉｃ株式会社 | ピペラジン化合物 |
| US8609696B2 (en) | 2008-12-18 | 2013-12-17 | Boehringer Ingelheim International Gmbh | Serotonin 5-HT2B receptor inhibitors |
| US20100234603A1 (en) | 2009-03-13 | 2010-09-16 | Xin Linghu | Process for Making Substituted Aryl Sulfone Intermediates |
| US20110039850A1 (en) | 2009-08-12 | 2011-02-17 | Mhairi Copland | Leukemia Treatment |
| CA2774573A1 (en) | 2009-10-09 | 2011-04-14 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| BR112012011823A2 (pt) | 2009-11-18 | 2019-09-24 | Novartis Ag | métodos e composições para tratar tumores sólidos e outras malignidades |
| AU2010347233B2 (en) | 2010-03-01 | 2015-06-18 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
| WO2011136292A1 (ja) | 2010-04-27 | 2011-11-03 | 田辺三菱製薬株式会社 | 新規アミド誘導体およびその医薬としての用途 |
| MX2012013130A (es) | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| ES2823350T3 (es) | 2010-07-29 | 2021-05-06 | Rigel Pharmaceuticals Inc | Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos |
| WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| JP5800786B2 (ja) | 2011-10-26 | 2015-10-28 | 田辺三菱製薬株式会社 | 新規アミド誘導体を有効成分として含有する医薬組成物 |
| US9139585B2 (en) | 2011-10-31 | 2015-09-22 | Merck Sharp & Dohme Corp. | Inhibitors of the Renal Outer Medullary Potassium channel |
| CN103360343B (zh) | 2012-03-30 | 2017-04-19 | 凯惠药业(上海)有限公司 | 一种哌嗪酰胺类化合物的制备方法 |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP3719019B1 (en) * | 2013-05-27 | 2022-01-19 | F. Hoffmann-La Roche AG | New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| WO2015101957A2 (en) | 2014-01-06 | 2015-07-09 | Rhizen Pharmaceuticals Sa | Novel glutaminase inhibitors |
| WO2015199206A1 (ja) * | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する６員環誘導体 |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| CN107176927B (zh) | 2016-03-12 | 2020-02-18 | 福建金乐医药科技有限公司 | 组蛋白去甲基化酶lsd1抑制剂 |
| SG11201807982UA (en) | 2016-03-16 | 2018-10-30 | Kura Oncology Inc | Substituted inhibitors of menin-mll and methods of use |
| MX2018015990A (es) | 2016-06-20 | 2019-10-07 | Univ Rutgers | Compuestos terapeuticos. |
| CN107540636A (zh) | 2016-06-29 | 2018-01-05 | 成都贝斯凯瑞生物科技有限公司 | 一种含氮杂环衍生物及其应用 |
| CN106317050B (zh) * | 2016-08-24 | 2018-11-23 | 烟台大学 | 一种苯基噻唑衍生物及其制备方法与应用 |
| JPWO2018159827A1 (ja) | 2017-03-03 | 2020-01-09 | 国立大学法人京都大学 | 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製 |
| TW201902875A (zh) | 2017-03-15 | 2019-01-16 | 美商亞瑟尼克斯公司 | 聯芳基哌啶醯胺化合物及其使用方法 |
| HRP20220991T1 (hr) | 2017-10-27 | 2022-11-11 | Boehringer Ingelheim International Gmbh | Derivati piridina i njihova terapeutska uporaba kao inhibitora trpc6 |
| SG11202003867SA (en) * | 2017-11-16 | 2020-05-28 | Principia Biopharma Inc | Immunoproteasome inhibitors |
| JP7291711B2 (ja) * | 2018-02-15 | 2023-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｒｐｃ６阻害剤 |
| EP3752503A1 (en) * | 2018-02-16 | 2020-12-23 | Boehringer Ingelheim International GmbH | Inhibitors of trpc6 |
-
2018
- 2018-10-25 HR HRP20220991TT patent/HRP20220991T1/hr unknown
- 2018-10-25 LT LTEP20197194.2T patent/LT3786160T/lt unknown
- 2018-10-25 US US16/170,178 patent/US10889568B2/en active Active
- 2018-10-25 KR KR1020207031025A patent/KR20200125758A/ko not_active Application Discontinuation
- 2018-10-25 SI SI201830924T patent/SI3700902T1/sl unknown
- 2018-10-25 CN CN201880070122.4A patent/CN111527078B/zh active Active
- 2018-10-25 MX MX2020004283A patent/MX2020004283A/es unknown
- 2018-10-25 US US16/170,154 patent/US10800757B2/en not_active Ceased
- 2018-10-25 SG SG10202011632RA patent/SG10202011632RA/en unknown
- 2018-10-25 EP EP18800513.6A patent/EP3700902B8/en active Active
- 2018-10-25 PL PL18800513.6T patent/PL3700902T3/pl unknown
- 2018-10-25 WO PCT/EP2018/079276 patent/WO2019081637A1/en active Application Filing
- 2018-10-25 FI FIEP18800513.6T patent/FI3700902T3/fi active
- 2018-10-25 SI SI201830732T patent/SI3786160T1/sl unknown
- 2018-10-25 PE PE2020000424A patent/PE20210154A1/es unknown
- 2018-10-25 UA UAA202003145A patent/UA128474C2/uk unknown
- 2018-10-25 SG SG11202003367TA patent/SG11202003367TA/en unknown
- 2018-10-25 LT LTEPPCT/EP2018/079276T patent/LT3700902T/lt unknown
- 2018-10-25 RS RS20220752A patent/RS63535B1/sr unknown
- 2018-10-25 PT PT201971942T patent/PT3786160T/pt unknown
- 2018-10-25 CA CA3078769A patent/CA3078769A1/en active Pending
- 2018-10-25 ES ES18800513T patent/ES2946274T3/es active Active
- 2018-10-25 HU HUE18800513A patent/HUE062460T2/hu unknown
- 2018-10-25 EP EP20197194.2A patent/EP3786160B1/en active Active
- 2018-10-25 HR HRP20230502TT patent/HRP20230502T1/hr unknown
- 2018-10-25 TW TW107137733A patent/TWI780246B/zh active
- 2018-10-25 AU AU2018355743A patent/AU2018355743B2/en active Active
- 2018-10-25 KR KR1020207014013A patent/KR102724066B1/ko active IP Right Grant
- 2018-10-25 PL PL20197194.2T patent/PL3786160T3/pl unknown
- 2018-10-25 TW TW109138850A patent/TWI780511B/zh active
- 2018-10-25 HU HUE20197194A patent/HUE059450T2/hu unknown
- 2018-10-25 PT PT188005136T patent/PT3700902T/pt unknown
- 2018-10-25 DK DK20197194.2T patent/DK3786160T3/da active
- 2018-10-25 RS RS20230382A patent/RS64271B1/sr unknown
- 2018-10-25 DK DK18800513.6T patent/DK3700902T3/da active
- 2018-10-25 BR BR112020007818-2A patent/BR112020007818A2/pt unknown
- 2018-10-25 JP JP2020523445A patent/JP7217273B6/ja active Active
- 2018-10-25 ES ES20197194T patent/ES2924933T3/es active Active
-
2020
- 2020-04-19 IL IL274039A patent/IL274039B/en unknown
- 2020-04-23 CL CL2020001097A patent/CL2020001097A1/es unknown
- 2020-04-26 SA SA520411843A patent/SA520411843B1/ar unknown
- 2020-04-27 PH PH12020550503A patent/PH12020550503A1/en unknown
- 2020-05-04 ZA ZA2020/02372A patent/ZA202002372B/en unknown
- 2020-09-22 IL IL277493A patent/IL277493B/en unknown
- 2020-10-02 CL CL2020002562A patent/CL2020002562A1/es unknown
- 2020-10-06 AU AU2020250185A patent/AU2020250185B2/en active Active
- 2020-10-08 JP JP2020170563A patent/JP6979502B2/ja active Active
- 2020-12-08 US US17/115,667 patent/US20210163449A1/en not_active Abandoned
-
2021
- 2021-05-28 US US17/334,097 patent/USRE49699E1/en active Active
-
2023
- 2023-06-07 CY CY20231100270T patent/CY1126109T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220991T1 (hr) | Derivati piridina i njihova terapeutska uporaba kao inhibitora trpc6 | |
| JP2005539000A5 (hr) | ||
| CN101460168B (zh) | 作为组胺h4受体调节剂的苯并咪唑-2-基吡啶 | |
| AU2020202167A1 (en) | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | |
| ES2564204T3 (es) | Derivados de pirrolopiridinil-pirimidin-2-il-amina | |
| CN101460483B (zh) | 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪 | |
| HRP20210094T1 (hr) | POSTUPAK PRIPRAVE DERIVATIVA OKSAZOLO[4,5-b]PIRIDINA I TIAZOLO[4,5-b]PIRIDINA KAO INHIBITORA IRAK4 NAMIJENJENIH LIJEČENJU RAKA | |
| HRP20191561T1 (hr) | Spojevi za modulaciju fxr (nr1h4) | |
| FI4157832T3 (fi) | Glp-1r-agonistien suola- ja kidemuotoja ja niiden käyttötarkoituksia | |
| JP2006511474A5 (hr) | ||
| TR201814710T4 (tr) | Yeni Geliştirilmiş Değişik Halkalı Heterosiklik Türevler Ve Bunların Kullanımı | |
| JP2016513714A5 (hr) | ||
| WO2008054748A3 (en) | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| WO1999016747A1 (fr) | Derives sulfonyle | |
| JP2009508949A5 (hr) | ||
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| WO2006060762A3 (en) | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| Zech et al. | Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone | |
| CA2903588C (en) | Purine derivatives as cb2 receptor agonists | |
| FI3831812T3 (fi) | Uusia 3,5-disubstituoituja pyridiini- ja 3,5-disubstituoituja pyridatsiinijohdannaisia ja niiden farmaseuttinen käyttö | |
| JP2010505836A5 (hr) | ||
| Ma et al. | Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents | |
| BR0209676A (pt) | Composto, processo para preparar o mesmo, uso de um composto, composição farmacêutica, e, métodos para o tratamento da dor, de distúrbios gastrintestinais funcionais, e da ansiedade. | |
| JPH11511749A (ja) | ２，４―ジアミノピリミジン誘導体 |